ORYZON awarded EU grant to further explore the role of iadademstat in oncological immunotherapy approaches al-immunotherapy

by Oryzon Genomics

1 year ago
Oryzon Genomics, BRAVE project

Oryzon Genomics, S.A., announced today the approval by the EU-intergovernmental organization EUREKA secretariat of funding for the BRAVE Project (Breaking immune Resistance of Advanced cancers by HERV...

ORYZON presents final data from Phase IIa ALICE trial in unfit AML patients with first-line treatment of iadademstat and azacitidine in oral presentation at ASH-2022

by Oryzon Genomics

1 year ago
Phase IIa ALICE trial, Iadademstat

Oryzon Genomics presents the final data from its Phase IIa ALICE trial, investigating iadademstat in combination with azacitidine in elderly or unfit patients with acute myeloid leukemia (AML), at the...

ORYZON announces FDA clearance of IND to initiate a collaborative Phase II basket study with iadademstat in R/R patients with Neuroendocrine carcinomas (NECs)

by Oryzon Genomics

1 year ago
Oryzon Genomics S.A., Neuroendocrine neoplasms, Iadademstat

Oryzon Genomics S. A., announced today that the FDA has approved the Investigational New Drug (IND) application to initiate a Phase II collaborative study with iadademstat in patients with relapsed/re...

ORYZON announces oral data presentation at the upcoming 64th American Society of Hematology annual conference

by Oryzon Genomics

Final data of Phase II ALICE trial in unfit AML patients treated with iadademstat and azacitidine

ORYZON reports results and corporate update for quarter ended September 30, 2022

by Oryzon Genomics

2 years ago
Oryzon Genomics

Oryzon Genomics, S.A., a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for the third...

ORYZON to give updates on corporate progress in October

by Oryzon Genomics

Oryzon Genomics, S.A., a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give ...

ORYZON to present preliminary blinded aggregate safety data from vafidemstat’s ongoing Phase IIb PORTICO trial in Borderline Personality Disorder

by Oryzon Genomics

2 years ago
Borderline Personality Disorder, vafidemstat, PORTICO trial

Oryzon today presents initial preliminary blinded aggregate safety data from its ongoing Phase IIb PORTICO trial, investigating vafidemstat in Borderline Personality Disorder (BDP), in a oral communic...

ORYZON collaborates with the CMT Research Foundation in the US

by Oryzon Genomics

Oryzon announced today the start of a preclinical collaboration with the CMT Research Foundation (CMTRF), a U.S.-based patient-led, non-profit organization focused on delivering treatments and cures f...

ORYZON reports results and corporate update for half-year ending June 30, 2022

by Oryzon Genomics

2 years ago
Iadademstat, Oryzon Genomics, S.A., Vafidemstat

The company has continued to make progress in this first semester in the clinical development of its iadademstat oncology and vafidemstat neurology programs.

ORYZON enters cooperative research and development agreement (CRADA) with U.S. National Cancer Institute to develop iadademstat in different cancers

by Oryzon Genomics

2 years ago
ORYZON, U.S. National Cancer Institute, iadademstat, Cooperative Research and Development Agreement (CRADA), LSD1 inhibitor

Under the terms of the agreement, Oryzon and the NCI will collaborate on potential further clinical development of Oryzon’s clinical stage LSD1 inhibitor, iadademstat, in different types of solid an...

ORYZON announces a New Financing through a Convertible Bond Program for a Total amount up to €20 Million over 30 months

by Oryzon Genomics

2 years ago
Oryzon Genomics S.A, Nice & Green

ORYZON announces FDA Orphan Drug Designation granted to iadademstat for treatment of Small Cell Lung Cancer

by Oryzon Genomics

2 years ago
iadademstat, Small Cell Lung Cancer, epigenetic enzyme LSD1, myeloid leukemia (AML)., SCLC

The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the company’s clinical stage LSD1 inhibitor iadademstat for the treatment of patients with small cell lung cancer (...